NeuroMetrix Reports High Level of Media Coverage for Quell in First Quarter

BOSTON--()--NeuroMetrix, Inc. (NASDAQ:NURO) today reported continued strong media attention focusing on the company’s innovative Quell® Wearable Pain Relief Technology. Highlights include:

“We are pleased with the increased attention Quell has attracted in the media during the first quarter of 2016,” said Frank McGillin, Senior Vice President and General Manager, Consumer of NeuroMetrix. “We are proud to see Quell reviewed in top tier media outlets such as Newsweek and Consumer Reports, and continued coverage in the Boston Globe.”

About Quell Wearable Pain Relief Technology

Quell is an easy-to-use, over-the-counter device for relief of chronic pain. This wearable device utilizes NeuroMetrix's patented technology to provide widespread pain relief. In a recent clinical study, Quell improved chronic pain in 81% of participants. Quell is currently available through select healthcare professionals, retailers and online at www.QuellRelief.com.

About NeuroMetrix

NeuroMetrix is an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

Contacts

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

$Cashtags

Contacts

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com